Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability

Citation for published version:

Digital Object Identifier (DOI):
10.1073/pnas.1202922109

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Proceedings of the National Academy of Sciences

Publisher Rights Statement:
Freely available online through the PNAS open access option.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability

Bilada Bilican\textsuperscript{a,b}, Andrea Serio\textsuperscript{a,b}, Sami J. Barnada\textsuperscript{a,d}, Agnes Lumi Nishimura\textsuperscript{c}, Gareth J. Sullivan\textsuperscript{b}, Monica Carrasco\textsuperscript{i}, Hemali P. Phatnani\textsuperscript{1}, Clare A. Puddifoot\textsuperscript{b}, David Story\textsuperscript{a,b}, Judy Fletcher\textsuperscript{b}, In-Hyun Park\textsuperscript{b}, Brad A. Friedman\textsuperscript{j}, George Q. Daley\textsuperscript{1}, David J. A. Wyllie\textsuperscript{b}, Giles E. Hardingham\textsuperscript{b}, Ian Wilmut\textsuperscript{b}, Steven Finkbeiner\textsuperscript{c,d}, Tom Maniatis\textsuperscript{1,4}, Christopher E. Shaw\textsuperscript{0,1,2}, and Siddharthan Chandran\textsuperscript{a,b,k,1,2}

\textsuperscript{a}Euan MacDonald Centre for Motor Neurone Disease Research, \textsuperscript{b}Medical Research Council Centre for Regenerative Medicine, \textsuperscript{c}Centre for Neuroregeneration, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom; \textsuperscript{d}Institute of Psychiatry, Medical Research Council Centre for Neurodegeneration Research, King’s College London, London SE5 8AF, United Kingdom; \textsuperscript{e}Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom; \textsuperscript{f}Yale Stem Cell Center, Department of Genetics, Yale School of Medicine, New Haven, CT 06520; \textsuperscript{g}Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032; \textsuperscript{h}Department of Biological Chemistry and Molecular Pharmacology, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115; \textsuperscript{i}Taube-Koret Center, Heilman Program, and Rodenberry Stem Cell Program, Gladstone Institute of Neurological Disease, San Francisco, CA 94158; \textsuperscript{j}Departments of Neurology and Physiology, University of California, San Francisco, CA 94143; and \textsuperscript{k}Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138

Contributed by Tom Maniatis, February 22, 2012 (sent for review January 10, 2012)

Transactive response DNA-binding (TDP-43) protein is the dominant disease protein in amyotrophic lateral sclerosis (ALS) and a subgroup of frontotemporal lobar degeneration (FTLD-TDP). Identification of mutations in the gene encoding TDP-43 (TARDBP) in familial ALS confirms a mechanistic link between misaccumulation of TDP-43 and neurodegeneration and provides an opportunity to study TDP-43 proteinopathies in human neurons generated from patient fibroblasts by using induced pluripotent stem cells (iPSCs). Here, we report the generation of iPSCs that carry the TDP-43 M337V mutation and their differentiation into neurons and functional motor neurons. Mutant neurons had elevated levels of soluble and detergent-resistant TDP-43 protein, decreased survival in longitudinal studies, and increased vulnerability to antagonism of the PI3K pathway. We conclude that expression of physiological levels of TDP-43 in human neurons is sufficient to reveal a mutation-specific cell-autonomous phenotype and strongly supports this approach for the study of disease mechanisms and for drug screening.

disease modeling | reprogramming | motor neuron disease

Lou Gehrig disease

Cytoplasmic accumulation of detergent-resistant transactive response DNA-binding (TDP-43) is a pathological hallmark of both sporadic and inherited FTLD-TDP (a subgroup of frontotemporal lobar degeneration) and ALS (except supersoxide dismutase 1 (SOD1) and fused in sarcoma (FUS) cases) and suggests a common pathological mechanism (1–4). Mutations in the gene encoding TDP-43 (TARDBP) have been identified in familial and sporadic ALS (5–8). Several in vitro and in vivo models established the toxicity of ALS-associated TDP-43 mutations, although the underlying mechanism is unclear (9, 10). Most cellular and animal models of ALS and FTLD-TDP pathogenesis involve overexpression of TDP-43 in nonneuronal or nonhuman cells and cannot be used to investigate the selective vulnerability of neurons or key molecular events that are unique to human cells. By contrast, induced pluripotent stem cells (iPSCs) (11–14) coupled with defined in vitro differentiation protocols (15–20) offer a model system to investigate disease mechanisms in a more physiological context. Here, we report the pathological effects of endogenous mutant TDP-43 in iPSC-derived human neurons from an ALS patient carrying the M337V mutation.

Results

Generation of iPSCs from TDP-43 M337V Fibroblasts. iPSC lines were established by using cells from a 56-yr-old man with ALS who had the TDP-43 M337V mutation (8, 21) and from two healthy controls. Fibroblasts (Fig. L4) were transduced with retroviral vectors encoding the reprogramming factors OCT4, SOX2, KLF4, and c-MYC as described in ref. 13. Colonies with compact human ES cell (hESC)-like morphology were expanded, and clonal lines were established, as described previously (21). All iPSCs used in the study exhibited silencing of the four transgenes and activation of endogenous OCT4, SOX2, and KLF4 (Fig. SL4). All iPSCs expressed the protein markers of pluripotency—OCT4, SOX2, and TRA-1–60 (Fig. 1 and Fig. S1B) —and had comparable levels of OCT4, SOX2, c-MYC, KLF4, and NANOG expression, as determined by quantitative RT-PCR (qRT-PCR) (Fig. 1G and Fig. S1C). Pluripotency was confirmed by teratoma formation (Fig. S1D) and bisulphite sequencing of the OCT4 promoter (13) (Fig. 1F). The genetic mutation was confirmed by direct sequencing of exon 6 in TARDBP in all lines (Fig. 1E). All clones were maintained a normal karyotype for more than 40 passages.

TDP-43 M337V Does Not Prevent Differentiation and Functional Maturation of Motor Neurons (MNs). To assess the effects of the TDP-43 M337V mutation on neural differentiation and function, we generated caudalized neuronal populations containing spinal MNs from iPSCs as described previously (21–23). Feeder-free iPSCs were differentiated into neuroectoderm by dual-SMAD signaling inhibition (21) (Fig. 2A and Fig. S24). Replating generated >90% RESTIN\textsuperscript{+} and SOXI\textsuperscript{+} cells (Fig. 2B and C). PAX6\textsuperscript{+} neuroepithelial cells (Fig. S2B) were treated with retinoic acid and purmorphamine to generate NKX6.1 and OLG2\textsuperscript{+} ventral spinal progenitors (Fig. 2A and Fig. S2C), which differentiated into MNs expressing Hb9, β-tubulin, SMII-32, and choline acetyltransferase (ChAT) (Fig. 2D–F and Fig. S2D) (23–25). Current-clamp recordings from ChAT\textsuperscript{+} MNs derived from M337V and control iPSCs revealed tetrodotoxin-sensitive action potentials.
and are representative of neurons TARDBP D OCT4 F + B Ad e B ∼ P 0.46 vs. 1.0 < F ChAT M337V neurons (Fig. 4 2.9%, D Establishment of iPSCs from patient HzB9 cells (118.89% fi B HB9::GFP; Fig. 5). To speci fi cally focus on MNs, we transfected M337V and control lanes in Figs. 3D and S5B). Again, M337V neurons had higher levels of soluble (2.6 ± 0.46 vs. 1.0 ± 0.13) and insoluble TDP-43 than controls (Fig. S4 A and B). We next investigated the subcellular distribution of TDP-43. Densitometric analysis revealed that strongly SMI-32+ neurons had significantly higher levels of nuclear TDP-43 than SMI-32− cells (118.89% ± 2.6% vs. 100% ± 2.9%, P < 0.001) (Fig. 4). However, the predominant nuclear localization of TDP-43 did not differ in M337V and control lanes (Fig. S4C). Subtle granular cytoplasmic staining was also detected in SMI-32+ and ChAT+ M337V neurons (Fig. 4 E and F and Fig. S4 E and F).

**M337V Increases Soluble and Detergent-Resistant TDP-43 Protein Levels.** A defining biochemical feature of diseased ALS and FTLD-TDP neural tissue is the accumulation of detergent-resistant ~43-kDa and C-terminal fragments of TDP-43 (29). We next examined the biochemical profile of TDP-43 in undifferentiated iPSCs. As determined by qRT-PCR, M337V and control iPSC lines expressed similar levels of TARDBP, the pluripotency markers TERT and REX1, and histone deacetylase 6 (HDAC6) mRNA (Fig. 3A), the latter of which is regulated by TDP-43 (30). Western blotting revealed that two independent M337V iPSC clones had higher levels of full-length TDP-43 in the soluble fraction and C-terminal TDP-43 fragments in the detergent-resistant fraction than controls (Fig. 3B). Importantly, TDP-43 fragmentation was not associated with conventional indices of apoptosis (cleaved poly(ADP-ribose) polymerase (PARP) (Fig. 3B) and annexin V/propidium iodide profiling (Fig. 3C)) (31–33).

Before establishing the biochemical profile of TDP-43 in MN-containing neuronal populations, we first verified that MN cultures derived from M337V and control 2 (Cont-2) had comparable expression levels of TARDBP, HB9, ChAT, and HDAC6 as determined by qRT-PCR analysis (Fig. S3A). Furthermore, MN cultures derived from both M337V and controls showed similar percentages of SMI-32+ cells by quantitative immunohistochemistry (Fig. S3B), altogether indicating comparable differentiation potential and composition of MN cultures at the point of assay. Immunoblot analysis revealed that M337V MN cultures from two independent clones had up to fourfold higher levels of soluble and detergent-resistant TDP-43 than Cont-2 MN cultures (Fig. 4A and B). Difference in TDP-43 levels in MN-containing populations was also evident with Cont-1 MN cultures (see control lanes in Figs. S3D and S5B). To determine whether this observation was independent of neuronal cell type and differentiation protocol, we generated caulizal neuronal populations that did not contain MNs and compared the amount of TDP-43 in cultures derived from mutant or control iPSCs (Fig. S4A and B). Again, M337V neurons had higher levels of soluble (2.6 ± 0.46 vs. 1.0 ± 0.13) and insoluble TDP-43 than controls (Fig. S4 C and D).

Whole-cell voltage-clamp recordings revealed functional NMDA, AMPA, and GABA receptors that typify MNs (Fig. S2 E and F). Mature MN cultures also exhibited spontaneous excitatory postsynaptic currents (EPSCs) that were blocked by 6-cyano-7-nitroquinolxaline-2,3-dione (CNOX) (Fig. 2G). Thus, both M337V and control iPSC lines generated phenotypically and functionally comparable MNs (26–28).
analysis, demonstrating a hazard ratio of 2.76, indicative of a 276% increase in the risk of death in M337V compared with control MNs.

We next determined whether the M337V mutation increased neuronal vulnerability to antagonism of key signaling pathways necessary for neuronal survival (37). MN-containing cultures were treated with U0126, a selective inhibitor of MAPK signaling; LY294002, a selective inhibitor of PI3K; or tunicamycin, an endoplasmic reticulum stressor. After 48 h of treatment, neuronal death was measured by lactate dehydrogenase (LDH) release. M337V and control MN cultures did not differ in their response to MAPK inhibition or tunicamycin ([Fig. S5](#) and [D]). However, M337V mutant lines 1 and 2 were significantly more vulnerable than controls were to LY294002 ([Fig. 5](#) and [C]), suggesting an intrinsic susceptibility to PI3K inhibition in neurons derived from M337V iPSCs.

**Discussion**

This paper describes an iPSC model of a TDP-43 proteinopathy in human MNs derived from a patient carrying a pathogenic TDP-43 mutation. Detailed cell-lineage and functional studies showed that the TDP-43 M337V mutation does not affect the functional maturation of neurons, including MNs. However, neurons carrying the mutation had increased levels of soluble and detergent-resistant TDP-43 and reduced survival under basal conditions, suggesting an inherent vulnerability. Mutant neurons were also more susceptible than control neurons to inhibition of PI3K, an essential signaling pathway in neurons (38). Thus, the mutant cells recapitulate key aspects of TDP-43 proteinopathies in vitro, including cell-autonomous neuronal degeneration and the accumulation of insoluble TDP-43. This model will facilitate mechanistic studies, the identification of therapeutic targets, and eventually the development of treatments for ALS and FTLD-TDP.

TDP-43 is intrinsically prone to aggregation, and ALS-linked mutations increase its toxicity, tendency to aggregate, and mislocalization to the cytoplasm (1, 3, 29, 39, 40). Although TDP-43 M337V and control neurons expressed equivalent levels of TARDBP mRNA, the mutant cells had significantly higher levels of soluble and detergent-resistant TDP-43. Previously, increased
stability of mutant TDP-43 proteins had only been observed in isogenic transformed cell lines (41). Our findings suggest that differences in TDP-43 protein levels result from a posttranslational mechanism rather than from transcriptional differences. In addition, the mutant proteins do not appear to interfere with the proposed autoregulatory feedback mechanism proposed for the control of TDP-43 mRNA levels (42, 43). The dominant missense mutations located in the C-terminal domain of TDP-43 might inhibit the turnover of the mutant protein or constrain protein quality-control pathways.

Despite the higher levels of TDP-43 in M337V neurons detected biochemically, we did not see more nuclear TDP-43 than in controls, as determined by immunofluorescence densitometry. However, SMI-32+ neurons had higher levels of nuclear TDP-43 in vitro, indicating that TDP-43 protein levels can differ between neuronal subtypes. In addition, punctate TDP-43 staining in the soma and cell processes was a consistent finding. This staining pattern is compatible with the involvement of TDP-43 in nucleocytoplasmic shuttling of RNA, the association of TDP-43 with RNA granules in somatodendrites, and the presence of TDP-43 in the microsome fraction of brainstem samples, suggesting active transport of TDP-43 along the axons (44–47).

Cellular and transgenic models of TDP-43 expression established that elevated levels of WT and mutant TDP-43 can be toxic and that levels of cytoplasmic, rather than nuclear, TDP-43 correlate with cellular toxicity (9, 10, 48). As shown by longitudinal fluorescence microscopy of live MNs, the risk of death was significantly increased by the M337V mutation, suggesting an inherent cell-autonomous toxicity of the mutation in MNs. Neuronal health and function are regulated by multiple signals, including brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor, and other trophic factors that...
signal through receptor tyrosine kinases (37). We demonstrated that M337V neurons were more sensitive to PI3K inhibition than control neurons were but showed no difference in vulnerability to inhibitors of the MAPK pathway or induction of endoplasmic reticulum stress through tunicamycin. Thus, the M337V mutation confers a specific susceptibility to PI3K inhibition, highlighting the importance of trophic factor-mediated signaling in the survival of human MNs. Even though most neurotrophic factors rely on both MAPK/ERK and PI3K/akt pathways for signal transduction, the contribution of these pathways to cell survival depends on the neuronal subtype and the combination of trophic factors (38). For instance, BDNF-induced MN survival requires the PI3K pathway (49), whereas retinal ganglion cells rely on both the PI3K and MAPK pathways in BDNF-dependent survival (50). Future studies involving the in vitro model that we established herein will focus on the contribution of different neurotrophic factors to the survival of TDP-43 M337V neurons.

In summary, our findings show that patient-derived TDP-43 M337V neurons recapitulate key biochemical aspects of TDP-43 proteinopathies and provide evidence that the M337V mutation in TDP-43 is toxic to iPSC-derived MNs, rendering them particularly susceptible to antagonism of PI3K signaling. Although this study was limited to a single patient line with subclones and controls, we identified a disease-specific phenotype in TDP-43 iPSC lines. Such lines will be useful for exploring the pathogenic mechanisms of other TDP-43 mutations and of different ALS-causing mutations under basal and stress paradigms. Finally, our findings demonstrate the utility of patient-specific iPSC lines in modeling the molecular pathogenesis of adult neurodegenerative disorders.

Materials and Methods

Generation of Human iPSCs. Fibroblasts from a normal male (56 y old; CRL-2465; ATCC), a normal female (40 y old; CRL-2524; ATCC), and from a 56-y-old male carrying the M337V TDP-43 mutation were reprogrammed as previously described (13). Details of iPSC characterization are provided in SI Materials and Methods.

Cell Culture. Human iPSC and hESC lines were maintained long term on CF-1 irradiated mouse embryonic fibroblasts, with KO-DMEM (Invitrogen) supplemented with 20% Knockout Serum Replacement (Invitrogen), 10 ng/mL basic FGF2 (PeproTech), 1 mM l-glutamine (Invitrogen), 100 mM 2-mercaptoethanol (Invitrogen), 1% penicillin/streptomycin (Invitrogen), and 1% nonessential amino acids. For the neural conversion, the cells were transitioned to feeder-free culture conditions in MTESR1 media (Stem Cell Technologies) and passaged three times before use. Details of neuronal differentiation and characterization are provided in SI Materials and Methods.

Primers and Antibodies. TaqMan and SYBR Green primer sequences are provided in Tables S1 and S2, respectively. Primary antibodies used are listed in Table S3.

ACKNOWLEDGMENTS. We thank Dr. Stephen Goldman for the generous gift of the H89:GFP plasmid. This work was made possible with support from the Euan MacDonald Centre (S.C.), the Fidelity Foundation (S.C.), the Motor Neurone Disease Association (C.E.S. and G.E.H.), the Wellcome Trust (G.E.H. and C.E.S.), the Motor Neurone Disease and Stroke (S.J.B. and S.F.), and the National Institutes of Neurological Disease and Stroke (S.J.B. and S.F.), and the National Institutes on Aging (S.F.).


Fig. 5. M337V TDP-43 neurons display selective vulnerability. (A) Representative image of an HB9::GFP* neuron used in real-time survival analysis. (B) Real-time survival analysis of M337V-1, M337V-2, Cont-1, and Cont-2 MN-containing cultures showing cumulative risk of death of HB9::GFP-transfected neurons. Pooled data from three independent differentiation experiments are shown (P < 0.001 between mutant and control groups, log-rank test). (C) Cytotoxicity in MN cultures derived from M337V and control iPSCs after treatment with LY294002 (40 μM) for 48 h. A total of 20,000 MN precursors per well were plated in a 96-well format and allowed to differentiate for 4 wk before treatments were started. Fluorescent LDH release measured with a FLUOstar OPTIMA plate reader served as a measure of cytotoxicity. Released LDH was normalized to total LDH for each well, and mock-treated samples were set to 100%. Percentage cytotoxicity for each treatment was determined as a factor of mock treatment for each cell line. Values are mean ± SEM. Data were analyzed by one-way ANOVA and post hoc Tukey test. *P < 0.05; M337V-1 vs. M337V-2, not significant; n = 3 independent experiments.